Comparative Pharmacology
Head-to-head clinical analysis: AZO GANTANOL versus SODIUM SULFACETAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZO GANTANOL versus SODIUM SULFACETAMIDE.
AZO GANTANOL vs SODIUM SULFACETAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenazopyridine is an azo dye with local analgesic effect on urinary tract mucosa via unknown mechanism; sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking the synthesis of folic acid and ultimately nucleic acid synthesis, leading to bacteriostatic activity.
AZO GANTANOL (phenazopyridine + sulfamethoxazole) is not a standard combination product. Assuming separate components: Sulfamethoxazole 800 mg and Trimethoprim 160 mg (as Bactrim DS) orally every 12 hours. For phenazopyridine: 200 mg orally three times daily after meals.
1-2 drops of 10% or 30% solution into conjunctival sac every 2-3 hours during waking hours for 7-10 days.
None Documented
None Documented
Sulfamethoxazole terminal half-life: 9-12 hours in adults with normal renal function (CrCl >80 mL/min); prolonged to 20-50 hours in CKD (CrCl <30 mL/min); phenazopyridine half-life: 9-11 hours
7-12 hours in normal renal function; prolonged to 20-50 hours in renal impairment.
Renal: 70% as sulfamethoxazole (30% acetylated), N5-acetylated metabolite accounts for 15%; fecal: 20% of dose excreted unchanged in bile; biliary: minor contribution (<5%)
Renal: 85-100% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category C
Category A/B
Sulfonamide Antibiotic
Sulfonamide Antibiotic